Form 8-K - Current report:
SEC Accession No. 0001213900-26-053075
Filing Date
2026-05-07
Accepted
2026-05-07 08:35:37
Documents
12
Period of Report
2026-05-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0289377-8k_cadrenal.htm   iXBRL 8-K 27311
2 PRESS RELEASE, ISSUED BY CADRENAL THERAPEUTICS, INC. ON MAY 6, 2026 ea028937701ex99-1.htm EX-99.1 42573
  Complete submission text file 0001213900-26-053075.txt   243819

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE cvkd-20260507.xsd EX-101.SCH 3014
4 XBRL LABEL FILE cvkd-20260507_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE cvkd-20260507_pre.xml EX-101.PRE 22358
15 EXTRACTED XBRL INSTANCE DOCUMENT ea0289377-8k_cadrenal_htm.xml XML 3327
Mailing Address 822 A1A NORTH SUITE 306 PONTE VEDRA FL 32082
Business Address 822 A1A NORTH SUITE 306 PONTE VEDRA FL 32082 904-300-0701
Cadrenal Therapeutics, Inc. (Filer) CIK: 0001937993 (see all company filings)

EIN.: 880860746 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41596 | Film No.: 26951066
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)